The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Open accessAbstract
We describe a strategy to comprehend signaling pathways active in lung cancer cells and targeted by dasatinib employing chemical proteomics to identify direct interacting proteins combined with immunoaffinity purification of tyrosine phosphorylated peptides corresponding to activated tyrosine kinases. We identified nearly 40 different kinase targets of dasatinib. These include SFK members (LYN, SRC, FYN, LCK, YES), non-receptor tyrosine kinases (FRK, BRK, ACK), and receptor tyrosine kinases (Ephrin receptors, DDR1, EGFR). Using quantitative phosphoproteomics we identified peptides corresponding to autophosphorylation sites of these tyrosine kinases that are inhibited in a concentration-dependent manner by dasatinib. Using drug resistant gatekeeper mutants, we show that SFK kinases, particularly SRC and FYN, as well as EGFR are relevant targets for dasatinib action. The combined mass spectrometry based approach described here provides a system-level view of dasatinib action in cancer cells and suggests both functional targets and rationale combinatorial therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“As acquired T790M mutations render cells resistant to dasatinib similar to that observed with erlotinib, this would limit effects of dasatinib in the resistant state (40).”
BackgroundA quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
Peri, S., Navarro, J. D., Amanchy, R., Kristiansen, T. Z., Jonnalagadda, C. K., Surendranath, V., Niranjan, V., Muthusamy, B., Gandhi, T. K. B., Gronborg, M., et al. (2003) · Genome Research · doi:10.1101/gr.1680803 · Cited by 1,089
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Src kinases as therapeutic targets for cancer
Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700
Self-citationILK, PINCH and parvin: the tIPP of integrin signalling
Legate, K. R., Montañez, E., Kudlacek, O., & Füssler, R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1789 · Cited by 676
Rix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., et al. (2007) · Blood · doi:10.1182/blood-2007-07-102061 · Cited by 671
Self-citationc-Src and cooperating partners in human cancer
Ishizawar, R., & Parsons, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.001 · Cited by 617 · cited 1×
“ALK and PDGFR, which is also a direct target of dasatinib, are known to signal through SRC kinases and may require the function of other dasatinib kinase targets for signal transduction (9).”
BackgroundMartin, G. S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35073094 · Cited by 599
Target profiling of small molecules by chemical proteomics
Rix, U., & Superti-Furga, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.216 · Cited by 575
Self-citationMechanism of biological synergy between cellular Src and epidermal growth factor receptor
Tice, D. A., Biscardi, J. S., Nickles, A. L., & Parsons, S. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1415 · Cited by 472
Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X.-M., Feldman, R. I., Hamilton, A. D., Polokoff, M., Nicosia, S. V., Herlyn, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0343 · Cited by 371
McDermott, U., Sharma, S. V., Dowell, L., Greninger, P., Montagut, C., Lamb, J., Archibald, H., Raudales, R., Tam, A., Lee, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707498104 · Cited by 356
Maa, M. C., Leu, T. H., McCarley, D. J., Schatzman, R. C., & Parsons, S. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6981 · Cited by 330
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Self-citationGlobal target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
Remsing Rix, L. L., Rix, U., Colinge, J., Hantschel, O., Bennett, K. L., Stranzl, T., Müller, A., Baumgartner, C., Valent, P., Augustin, M., et al. (2009) · Leukemia · doi:10.1038/leu.2008.334 · Cited by 284
Self-citationEpidermal‐Growth‐Factor‐Dependent Activation of the Src‐Family Kinases
Osherov, N., & Levitzki, A. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.1047b.x · Cited by 281
Park, S. I., Zhang, J., Phillips, K. A., Araujo, J. C., Najjar, A. M., Volgin, A. Y., Gelovani, J. G., Kim, S.-J., Wang, Z., & Gallick, G. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2997 · Cited by 233
Du, J., Bernasconi, P., Clauser, K. R., Mani, D. R., Finn, S. P., Beroukhim, R., Burns, M., Julian, B., Peng, X. P., Hieronymus, H., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1513 · Cited by 232
Shah, N. P., Kasap, C., Weier, C., Balbas, M., Nicoll, J. M., Bleickardt, E., Nicaise, C., & Sawyers, C. L. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.001 · Cited by 230
Stover, D. R., Becker, M., Liebetanz, J., & Lydon, N. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.26.15591 · Cited by 218
Song, L., Morris, M., Bagui, T., Lee, F. Y., Jove, R., & Haura, E. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4620 · Cited by 204
Self-citationGandhi, J., Zhang, J., Xie, Y., Soh, J., Shigematsu, H., Zhang, W., Yamamoto, H., Peyton, M., Girard, L., Lockwood, W. W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004576 · Cited by 198
Bandyopadhyay, A., Agyin, J. K., Wang, L., Tang, Y., Lei, X., Story, B. M., Cornell, J. E., Pollock, B. H., Mundy, G. R., & Sun, L.-Z. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3565 · Cited by 185
Margolis, B., Silvennoinen, O., Comoglio, F., Roonprapunt, C., Skolnik, E., Ullrich, A., & Schlessinger, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.8894 · Cited by 169
Zhang, Q., Thomas, S. M., Xi, S., Smithgall, T. E., Siegfried, J. M., Kamens, J., Gooding, W. E., & Grandis, J. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0504 · Cited by 167
Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression
HEROULT, M., SCHAFFNER, F., & AUGUSTIN, H. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.028 · Cited by 160
Zhang, J., Kalyankrishna, S., Wislez, M., Thilaganathan, N., Saigal, B., Wei, W., Ma, L., Wistuba, I. I., Johnson, F. M., & Kurie, J. M. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060706 · Cited by 157
Takanami, I. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-1 · Cited by 155
Kobayashi, S. S., Shimamura, T., Monti, S., Steidl, U. G., Hetherington, C. J., Lowell, A. M., Golub, T. R., Meyerson, M. M., Tenen, D. G., Shapiro, G. I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2318 · Cited by 151
Ford, C. E., Lau, S. A., Zhu, C., Andersson, T., Tsao, M., & Vogel, W. F. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603614 · Cited by 146
Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1
van der Horst, E. H., Degenhardt, Y., Strelow, A., Slavin, A., Chinn, L., Orf, J. N., Rong, M., Li, S., See, L.-H., Nguyen, K. C. Q., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508014102 · Cited by 145
Ostrander, J. H., Daniel, A. R., Lofgren, K. A., Kleer, C. G., & Lange, C. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3409 · Cited by 141
Mueller, K. L., Hunter, L. A., Ethier, S. P., & Boerner, J. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0132 · Cited by 136
Puri, N., Khramtsov, A., Ahmed, S., Nallasura, V., Hetzel, J. T., Jagadeeswaran, R., Karczmar, G. S., & Salgia, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4416 · Cited by 126
Kamalati, T., Jolin, H. E., Fry, M., & Crompton, M. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203931 · Cited by 121
Shen, F., Lin, Q., Gu, Y. H., Childress, C., & Yang, W. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-02-0142 · Cited by 102
Biochemical Properties of the Cdc42-associated Tyrosine Kinase ACK1
Yokoyama, N. N., & Miller, W. T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306716200 · Cited by 80
Satoh, T., Kato, J., Nishida, K., & Kaziro, Y. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00449-8 · Cited by 61
Coker, K. J., Staros, J. V., & Guyer, C. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.6967 · Cited by 54
Fu, Y.-N., Yeh, C.-L., Cheng, H.-Y. H., Yang, C.-H., Tsai, S., Huang, S.-F., & Chen, Y.-R. (2008) · Oncogene · doi:10.1038/sj.onc.1210684 · Cited by 42
Yang, W., Lin, Q., Zhao, J., Guan, J., & Cerione, R. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104819200 · Cited by 33
Requirement of Activated Cdc42-Associated Kinase for Survival of v-Ras-Transformed Mammalian Cells
Nur‐E‐Kamal, A., Zhang, A., Keenan, S. M., Wang, X. I., Seraj, J., Satoh, T., Meiners, S. A., & Welsh, W. J. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0152 · Cited by 27
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Lupberger, J., Zeisel, M. B., Xiao, F., Thumann, C., Fofana, I., Zona, L., Davis, C., Mee, C. J., Turek, M., Gorke, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2341 · Cited by 706
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 614
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
Hammerman, P. S., Sos, M. L., Ramos, A. H., Xu, C., Dutt, A., Zhou, W., Brace, L. E., Woods, B. A., Lin, W., Zhang, J., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0005 · Cited by 482
Self-citationAgeing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Metadata
- Authors
- Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K. L., Gao, J., Song, L., Eschrich, S., Superti-Furga, G., Koomen, J., & Haura, E. B.
- Venue
- Nature Chemical Biology
- Published
- 2010-02-28
- Volume
- 6
- Issue
- 4
- Pages
- 291-299
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2071437006
- Cited by
- 283
- References
- 50
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.